Short Interest in Sunshine Biopharma, Inc. (NASDAQ:SBFM) Drops By 27.2%

Sunshine Biopharma, Inc. (NASDAQ:SBFMGet Free Report) was the target of a large decline in short interest in March. As of March 31st, there was short interest totalling 706,700 shares, a decline of 27.2% from the March 15th total of 971,000 shares. Approximately 0.8% of the shares of the stock are short sold. Based on an average trading volume of 21,680,000 shares, the days-to-cover ratio is presently 0.0 days.

Sunshine Biopharma Price Performance

Shares of SBFM traded down $0.01 on Friday, hitting $0.08. The company’s stock had a trading volume of 16,534,116 shares, compared to its average volume of 24,975,060. The company has a market capitalization of $7.97 million, a PE ratio of -0.42 and a beta of 1.17. Sunshine Biopharma has a fifty-two week low of $0.04 and a fifty-two week high of $1.40. The company has a 50 day moving average price of $0.09 and a 200 day moving average price of $0.21.

Sunshine Biopharma’s stock is going to reverse split on Wednesday, April 17th. The 1-100 reverse split was announced on Wednesday, April 17th. The number of shares owned by shareholders will be adjusted after the closing bell on Wednesday, April 17th.

Institutional Trading of Sunshine Biopharma

Institutional investors and hedge funds have recently made changes to their positions in the business. Virtu Financial LLC raised its position in shares of Sunshine Biopharma by 242.8% during the 2nd quarter. Virtu Financial LLC now owns 47,861 shares of the company’s stock valued at $52,000 after acquiring an additional 33,898 shares during the last quarter. Citadel Advisors LLC bought a new stake in shares of Sunshine Biopharma in the 4th quarter valued at $50,000. Bank of Montreal Can bought a new stake in shares of Sunshine Biopharma in the 2nd quarter valued at $40,000. Jane Street Group LLC bought a new stake in shares of Sunshine Biopharma in the 1st quarter valued at $31,000. Finally, Two Sigma Investments LP bought a new stake in shares of Sunshine Biopharma in the 3rd quarter valued at $29,000. Institutional investors own 41.98% of the company’s stock.

Sunshine Biopharma Company Profile

(Get Free Report)

Sunshine Biopharma, Inc, a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; SBFM-PL4, an anti-coronavirus treatment compound; and K1.1 mRNA molecules used as anti-cancer agents.

See Also

Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with's FREE daily email newsletter.